Full-Time

Senior Clinical Operations Manager

Lumen Bioscience

Lumen Bioscience

51-200 employees

Develops and commercializes biologic drugs

Compensation Overview

$140k - $150k/yr

+ Stock Bonus

Seattle, WA, USA

In Person

Category
Biology & Biotech (2)
,
Required Skills
Google Cloud Platform
Requirements
  • MS/PharmD/PhD preferred; BS with robust experience considered
  • Minimum of 12 years of clinical operations experience, including program/CRO oversight and people management
  • Demonstrated ownership of Phase I–III trials and experience supporting Investigational New Drug applications/Clinical Trial Applications filings
  • Experience in biologics or oral/edible drug delivery modalities
  • Prior inspection response ownership or regulatory submission leadership
  • Strong working knowledge of Clinical Trial Management Systems, eClinical Solutions, eClinical Data Management platforms (CTMS, electronic Trial Master File systems, electronic Data Capture)
  • Proficiency in clinical trial management systems (CTMS), electronic data capture (EDC) systems, and other relevant software applications
  • Deep familiarity with ICH-Good Clinical Practice, FDA/European Medicines Agency regulations and inspection processes
  • Strong leadership, communication, negotiation and problem-solving skills
  • ACRP or SOCRA certification
  • Physical requirement: Ability to work on-site in Seattle, WA
Responsibilities
  • Lead operational strategy and execution for one or more clinical development programs (Phase I–III or platform trials)
  • Create program timelines, resourcing plans, and run-rate forecasts
  • Oversee site selection/activation strategy, enrollment performance, monitoring strategy (risk-based monitoring), Site Initiation Visits, close-out, and vendor deliverables
  • Escalate and resolve issues that threaten timelines or data quality
  • Mentor Clinical Operations Managers/Clinical Research Associates; recruit, mentor, and develop talent; run performance reviews and succession plans
  • Manage vendor Key Performance Indicators and Service Level Agreements, run vendor governance, and drive performance improvements
  • Hold Contract Research Organizations accountable for timelines, data quality, monitoring, and Trial Master File completeness
  • Own program budgets; provide accurate forecasting and control spend
  • Approve study-level operational expenses within delegated authority
  • Ensure inspection readiness and lead remediation after internal or external audits
  • Coordinate and respond to inspection/regulatory submissions and agency inquiries
  • Ensure eTMF completeness, timely monitoring visit documentation, query resolution, and adherence to GCP/ICH and applicable regulations (FDA, EMA, local)
  • Work closely with Data Management and Safety to ensure integrated delivery
  • Drive continuous improvement; implement Standard Operating Procedures and automation (CTMS/EDC/eTMF optimizations) to increase efficiency and quality
  • Present program status to leadership and the executive team

Lumen Bioscience develops and commercializes biologic drugs using a patented production platform that makes drug development faster, cheaper, and scalable. Biologic drugs are therapeutic proteins produced from living cells, and Lumen Bio uses its technology to manufacture these biologics more efficiently and at a lower cost, enabling broader access for patients. The company’s products are designed to treat conditions like inflammatory bowel disease and metabolic diseases, and it serves hospitals, healthcare providers, and patients. Unlike traditional biopharma methods that can be slow and expensive, Lumen Bio focuses on scaling production and reducing development time to offer more affordable biologics. Its goal is to bring safe and effective biologic therapies to a wider patient population, address neglected health issues, and improve outcomes for diseases with high unmet need.

Company Size

51-200

Company Stage

Series C

Total Funding

$167.6M

Headquarters

Seattle, Washington

Founded

2017

Simplify Jobs

Simplify's Take

What believers are saying

  • FDA Fast Track Designation accelerates LMN-201 development for recurrent C. difficile infection treatment.
  • DoD funding of $16.2 million and $5.5 million supports late-stage trials and vaccine development.
  • Novo Nordisk collaboration validates platform for obesity and cardiometabolic disease applications.

What critics are saying

  • RePreve main cohort fails to meet sustained clinical cure endpoint, blocking FDA approval.
  • Seres Therapeutics' VOWST dominates recurrent CDI market with proven 88% recurrence reduction.
  • Patient recruitment stalls due to trial fatigue, delaying topline data and depleting capital.

What makes Lumen Bioscience unique

  • Spirulina-based platform reduces biologic manufacturing costs two to three orders of magnitude versus traditional methods.
  • Oral delivery enables daily dosing for biologics previously requiring injection or infusion administration.
  • LMN-201 achieved 100% initial clinical cure rate in RePreve Phase 2/3 sentinel cohort of 21 patients.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Lumen Bioscience who can refer or advise you

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Company Match

Unlimited Paid Time Off

Monthly Wellness Program

Free onsite parking or public transportation subsidies

Comprehensive parental leave policies

Life Insurance

Short & Long-Term Disability

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

4%
GeekWire
Oct 8th, 2025
Fresh off $30M round, Seattle startup Lumen Bioscience adds Microsoft vet Jeff Raikes to board

Fresh off $30M round, seattle startup Lumen Bioscience adds Microsoft vet Jeff Raikes to board. Seattle-based biotech startup Lumen Bioscience raised a $30 million Series C extension and announced several leadership updates. WestRiver Group led the latest funding round, bringing the company's total capital raised to $186.8 million. The new investment will help Lumen accelerate its pipeline of orally delivered biologic drugs made from genetically engineered spirulina, a type of blue-green algae. Lumen's technology platform enables therapeutic proteins - traditionally injected or infused - to be produced and delivered orally in an edible, low-cost form. The 110-person company is targeting diseases that act in or originate from the gastrointestinal tract. It recently reported promising Phase 2 results from LMN-201, Lumen's lead candidate for recurrent C. difficile infection. The company also announced that Jeff Raikes, former Microsoft president and Gates Foundation CEO, joined Lumen's board as an independent director. * Erik Anderson, founder and CEO of WestRiver Group, was elected vice chairman of the board. * Internal promotions include Nhi Khuong to EVP and Kole Krieger to SVP, while Dr. David Saunders, a retired U.S. Army colonel and clinical trialist, joined the clinical development team. The company has grown its workforce by nearly 40% since 2023 and opened a second manufacturing facility. Lumen is led by CEO Brian Finrow, a former senior vice president at Adaptive Biotechnologies, and Chief Science Officer Jim Roberts, the former head of basic sciences at the Fred Hutchinson Cancer Research Institute. They co-founded the startup in 2017.

Gulf & Main Magazine
Oct 8th, 2025
Lumen Bioscience Expands Board, Raises $30M

Lumen Bioscience has expanded its board and leadership team following a $30 million Series C financing extension led by WestRiver Group, with participation from the Gates Foundation and others. Jeff Raikes joins as an independent director, while Nhi Khuong and Kole Krieger receive promotions. David Saunders joins the clinical team. The funding will accelerate late-stage clinical programs and commercial readiness, with a focus on spirulina-based GMP manufacturing for oral biologics.

Daily Dispatch
Feb 6th, 2024
Opyl's Opin secures patient recruitment contract for US-based Lumen Bioscience

Opyl's Opin secures patient recruitment contract for US-based Lumen Bioscience.

William Reed Business Media
Nov 30th, 2023
Lumen Bioscience bags $5.5 million to develop needle-free vaccines

Lumen Bioscience, a clinical-stage biopharma company developing biologic drugs for highly prevalent disease, has received $5.5 million in new funding from the U.S. Department of Defense, to develop technologies for needle-free vaccines.

PR Newswire
Oct 17th, 2023
Lumen Bioscience awarded $16.2 million in DoD funding to advance LMN-201 through late-stage trials

SEATTLE, Oct. 17, 2023 /PRNewswire/ -- Lumen Bioscience -a clinical-stage biotechnology company developing biologic drugs for highly prevalent diseases, today announced it was awarded $16.2 million by the U.S. Department of Defense to advance LMN-201 through late-stage trials.